Management of high-risk medulloblastoma

Area of Science:

• Pediatric neuro-oncology
• Cancer genomics
• Clinical trial design

Background:

• Medulloblastoma is the most common pediatric malignant brain tumor.
• Current treatment relies on clinical risk stratification (age, resection, metastasis).
• High-risk cases involve metastatic disease or incomplete resection (>1.5 cm² residual tumor).

Purpose of the Study:

• To review the 4-decade evolution of high-risk medulloblastoma management.
• To highlight recent changes in defining high-risk medulloblastoma.
• To incorporate advances in understanding medulloblastoma's molecular heterogeneity.

Main Methods:

• Literature review of clinical management strategies.
• Analysis of risk stratification criteria over time.
• Integration of molecular subtyping findings.

Main Results:

• Treatment paradigms have shifted significantly over the past 40 years.
• Molecular insights are redefining high-risk patient classification.
• Multimodal therapy (surgery, radiation, chemotherapy) remains central.

Conclusions:

• Evolving understanding of medulloblastoma heterogeneity impacts risk assessment.
• Management strategies continue to adapt based on clinical and molecular data.
• Improved outcomes for pediatric brain tumors are driven by these advancements.